Altimmune, Inc.
Status: Publicly traded
Direct answer
Altimmune, Inc. is publicly traded on NASDAQ under the ticker ALT.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic...
Can you invest in Altimmune, Inc.?
Yes. Altimmune, Inc. trades publicly on NASDAQ as ALT.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Altimmune, Inc.
Detailed equity research is provided by MarketSnap.